secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001178913-25-001763
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion Therapeutics Q1 2025 net loss $1.7M; cash $6.2M; SIL204 shows ~70-80% tumor reduction
--------------------------------------------------------------------------------

- Net loss $1.7M in Q1 2025 vs $1.4M in Q1 2024; total operating expenses $1.7M (R&D $0.6M, G&A $1.1M).
- Cash and cash equivalents $6.2M as of Mar 31, 2025, up from $1.2M in Dec 31, 2024, after ~$9.2M gross raised.
- SIL204 orthotopic data: ~70% tumor cell reduction in AsPC-1 (G12D) and ~80% in BxPC-3 by day 28; reduced metastases.
- Expanded dual-route (systemic + intratumoral) development strategy for SIL204; clinical trials targeted for H1 2026.
- Post-quarter strategic collaboration with Catalent for formulation and clinical manufacturing of SIL204.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325001763/0001178913-25-001763-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325001763/zk2533189.htm
  HTML page:      https://secwatch.observer/filing/0001178913-25-001763

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer